These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. Harrington WJ; Sheremata WA; Snodgrass SR; Emerson S; Phillips S; Berger JR AIDS Res Hum Retroviruses; 1991 Dec; 7(12):1031-4. PubMed ID: 1812944 [TBL] [Abstract][Full Text] [Related]
4. Multiple clinical manifestation of HTLV1 infection in a single patient. Narayan D; DaSilva D; Doshi M West Indian Med J; 2003 Dec; 52(4):322-4. PubMed ID: 15040072 [TBL] [Abstract][Full Text] [Related]
5. [Potentially treatable subacute forms of infection due to the HTLV-1]. Carod-Artal FJ; Melo M; Alves R; Brenner C; del Negro MC Rev Neurol; 2000 Jul 1-15; 31(1):32-5. PubMed ID: 10948579 [TBL] [Abstract][Full Text] [Related]
6. Plasmapheresis to treat human T lymphotropic virus type I-associated myelopathy. Matsuo H; Nakamura T; Shibayama K; Motomura M; Nagasato K; Takeo G; Tsujihata M; Nagataki S Curr Stud Hematol Blood Transfus; 1990; (57):198-207. PubMed ID: 2272201 [No Abstract] [Full Text] [Related]
8. Successful 2-year therapy with systemic interferon-alpha for HTLV-I associated myelopathy. Gazzola P; Cocito L; De Maria A; Gabutti G; Mancardi GL J Neurol Sci; 1999 Jan; 162(2):205-7. PubMed ID: 10202989 [No Abstract] [Full Text] [Related]
9. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. Kataoka A; Imai H; Inayoshi S; Tsuda T J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1213-6. PubMed ID: 8229033 [TBL] [Abstract][Full Text] [Related]
10. Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Boostani R; Vakili R; Hosseiny SS; Shoeibi A; Fazeli B; Etemadi MM; Sabet F; Valizade N; Rezaee SA Neurotherapeutics; 2015 Oct; 12(4):887-95. PubMed ID: 26174324 [TBL] [Abstract][Full Text] [Related]
11. The effect of zidovudine on chronic myelopathy associated with HTLV-1. Gout O; Gessain A; Iba-Zizen M; Kouzan S; Bolgert F; de Thé G; Lyon-Caen O J Neurol; 1991 Apr; 238(2):108-9. PubMed ID: 1856736 [No Abstract] [Full Text] [Related]
12. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. Saito M; Nakagawa M; Kaseda S; Matsuzaki T; Jonosono M; Eiraku N; Kubota R; Takenouchi N; Nagai M; Furukawa Y; Usuku K; Izumo S; Osame M J Infect Dis; 2004 Jan; 189(1):29-40. PubMed ID: 14702150 [TBL] [Abstract][Full Text] [Related]
13. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Nishiura Y; Nakamura T; Fukushima N; Nakamura H; Ida H; Aramaki T; Eguchi K Antivir Ther; 2009; 14(4):533-42. PubMed ID: 19578238 [TBL] [Abstract][Full Text] [Related]
14. [Tropical spastic paraparesis in a non tropical region]. Pias-Peleteiro L; Pias-Peleteiro JM; Arias M Rev Neurol; 2015 Oct; 61(8):357-62. PubMed ID: 26461129 [TBL] [Abstract][Full Text] [Related]